Peptide Based Metabolic Disorders Therapeutics Market - Global Outlook and Forecast 2023-2028

Report ID: 980698 | Published Date: Jan 2025 | No. of Page: 70 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Peptide Based Metabolic Disorders Therapeutics Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Peptide Based Metabolic Disorders Therapeutics Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Peptide Based Metabolic Disorders Therapeutics Overall Market Size
    2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size: 2021 VS 2028
    2.2 Global Peptide Based Metabolic Disorders Therapeutics Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Peptide Based Metabolic Disorders Therapeutics Players in Global Market
    3.2 Top Global Peptide Based Metabolic Disorders Therapeutics Companies Ranked by Revenue
    3.3 Global Peptide Based Metabolic Disorders Therapeutics Revenue by Companies
    3.4 Top 3 and Top 5 Peptide Based Metabolic Disorders Therapeutics Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Peptide Based Metabolic Disorders Therapeutics Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Peptide Based Metabolic Disorders Therapeutics Players in Global Market
        3.6.1 List of Global Tier 1 Peptide Based Metabolic Disorders Therapeutics Companies
        3.6.2 List of Global Tier 2 and Tier 3 Peptide Based Metabolic Disorders Therapeutics Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Peptide Based Metabolic Disorders Therapeutics Market Size Markets, 2021 & 2028
        4.1.2 Exenatide
        4.1.3 Liraglutide
        4.1.4 Others
    4.2 By Type - Global Peptide Based Metabolic Disorders Therapeutics Revenue & Forecasts
        4.2.1 By Type - Global Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2022
        4.2.2 By Type - Global Peptide Based Metabolic Disorders Therapeutics Revenue, 2023-2028
        4.2.3 By Type - Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Peptide Based Metabolic Disorders Therapeutics Market Size, 2021 & 2028
        5.1.2 Hospital Pharmacies
        5.1.3 Retail Pharmacies
        5.1.4 Online Pharmacies
    5.2 By Application - Global Peptide Based Metabolic Disorders Therapeutics Revenue & Forecasts
        5.2.1 By Application - Global Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2022
        5.2.2 By Application - Global Peptide Based Metabolic Disorders Therapeutics Revenue, 2023-2028
        5.2.3 By Application - Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Peptide Based Metabolic Disorders Therapeutics Market Size, 2021 & 2028
    6.2 By Region - Global Peptide Based Metabolic Disorders Therapeutics Revenue & Forecasts
        6.2.1 By Region - Global Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2022
        6.2.2 By Region - Global Peptide Based Metabolic Disorders Therapeutics Revenue, 2023-2028
        6.2.3 By Region - Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2028
        6.3.2 US Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.3.3 Canada Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.3.4 Mexico Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2028
        6.4.2 Germany Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.4.3 France Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.4.4 U.K. Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.4.5 Italy Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.4.6 Russia Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.4.7 Nordic Countries Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.4.8 Benelux Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2028
        6.5.2 China Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.5.3 Japan Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.5.4 South Korea Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.5.5 Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.5.6 India Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2028
        6.6.2 Brazil Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.6.3 Argentina Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2028
        6.7.2 Turkey Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.7.3 Israel Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.7.4 Saudi Arabia Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
        6.7.5 UAE Peptide Based Metabolic Disorders Therapeutics Market Size, 2017-2028
7 Players Profiles
    7.1 AstraZeneca
        7.1.1 AstraZeneca Corporate Summary
        7.1.2 AstraZeneca Business Overview
        7.1.3 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Major Product Offerings
        7.1.4 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Revenue in Global Market (2017-2022)
        7.1.5 AstraZeneca Key News
    7.2 Ingro Finanz (Bachem)
        7.2.1 Ingro Finanz (Bachem) Corporate Summary
        7.2.2 Ingro Finanz (Bachem) Business Overview
        7.2.3 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Major Product Offerings
        7.2.4 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Revenue in Global Market (2017-2022)
        7.2.5 Ingro Finanz (Bachem) Key News
    7.3 Eli Lilly
        7.3.1 Eli Lilly Corporate Summary
        7.3.2 Eli Lilly Business Overview
        7.3.3 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Major Product Offerings
        7.3.4 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Revenue in Global Market (2017-2022)
        7.3.5 Eli Lilly Key News
    7.4 Ipsen
        7.4.1 Ipsen Corporate Summary
        7.4.2 Ipsen Business Overview
        7.4.3 Ipsen Peptide Based Metabolic Disorders Therapeutics Major Product Offerings
        7.4.4 Ipsen Peptide Based Metabolic Disorders Therapeutics Revenue in Global Market (2017-2022)
        7.4.5 Ipsen Key News
    7.5 Merck
        7.5.1 Merck Corporate Summary
        7.5.2 Merck Business Overview
        7.5.3 Merck Peptide Based Metabolic Disorders Therapeutics Major Product Offerings
        7.5.4 Merck Peptide Based Metabolic Disorders Therapeutics Revenue in Global Market (2017-2022)
        7.5.5 Merck Key News
    7.6 Novo Nordisk
        7.6.1 Novo Nordisk Corporate Summary
        7.6.2 Novo Nordisk Business Overview
        7.6.3 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Major Product Offerings
        7.6.4 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Revenue in Global Market (2017-2022)
        7.6.5 Novo Nordisk Key News
    7.7 PolyPeptide Group
        7.7.1 PolyPeptide Group Corporate Summary
        7.7.2 PolyPeptide Group Business Overview
        7.7.3 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Major Product Offerings
        7.7.4 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Revenue in Global Market (2017-2022)
        7.7.5 PolyPeptide Group Key News
    7.8 Teva Pharmaceutical
        7.8.1 Teva Pharmaceutical Corporate Summary
        7.8.2 Teva Pharmaceutical Business Overview
        7.8.3 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Major Product Offerings
        7.8.4 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Revenue in Global Market (2017-2022)
        7.8.5 Teva Pharmaceutical Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Peptide Based Metabolic Disorders Therapeutics Market Opportunities & Trends in Global Market
    Table 2. Peptide Based Metabolic Disorders Therapeutics Market Drivers in Global Market
    Table 3. Peptide Based Metabolic Disorders Therapeutics Market Restraints in Global Market
    Table 4. Key Players of Peptide Based Metabolic Disorders Therapeutics in Global Market
    Table 5. Top Peptide Based Metabolic Disorders Therapeutics Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Peptide Based Metabolic Disorders Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Peptide Based Metabolic Disorders Therapeutics Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Peptide Based Metabolic Disorders Therapeutics Product Type
    Table 9. List of Global Tier 1 Peptide Based Metabolic Disorders Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Peptide Based Metabolic Disorders Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Peptide Based Metabolic Disorders Therapeutics Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Peptide Based Metabolic Disorders Therapeutics Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Peptide Based Metabolic Disorders Therapeutics Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Peptide Based Metabolic Disorders Therapeutics Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2023-2028
    Table 30. AstraZeneca Corporate Summary
    Table 31. AstraZeneca Peptide Based Metabolic Disorders Therapeutics Product Offerings
    Table 32. AstraZeneca Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), (2017-2022)
    Table 33. Ingro Finanz (Bachem) Corporate Summary
    Table 34. Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Product Offerings
    Table 35. Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), (2017-2022)
    Table 36. Eli Lilly Corporate Summary
    Table 37. Eli Lilly Peptide Based Metabolic Disorders Therapeutics Product Offerings
    Table 38. Eli Lilly Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), (2017-2022)
    Table 39. Ipsen Corporate Summary
    Table 40. Ipsen Peptide Based Metabolic Disorders Therapeutics Product Offerings
    Table 41. Ipsen Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), (2017-2022)
    Table 42. Merck Corporate Summary
    Table 43. Merck Peptide Based Metabolic Disorders Therapeutics Product Offerings
    Table 44. Merck Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), (2017-2022)
    Table 45. Novo Nordisk Corporate Summary
    Table 46. Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Product Offerings
    Table 47. Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), (2017-2022)
    Table 48. PolyPeptide Group Corporate Summary
    Table 49. PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Product Offerings
    Table 50. PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), (2017-2022)
    Table 51. Teva Pharmaceutical Corporate Summary
    Table 52. Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Product Offerings
    Table 53. Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Peptide Based Metabolic Disorders Therapeutics Segment by Type in 2021
    Figure 2. Peptide Based Metabolic Disorders Therapeutics Segment by Application in 2021
    Figure 3. Global Peptide Based Metabolic Disorders Therapeutics Market Overview: 2020
    Figure 4. Key Caveats
    Figure 5. Global Peptide Based Metabolic Disorders Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Peptide Based Metabolic Disorders Therapeutics Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Peptide Based Metabolic Disorders Therapeutics Revenue in 2021
    Figure 8. By Type - Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    Figure 12. US Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    Figure 16. Germany Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 17. France Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    Figure 24. China Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 28. India Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    Figure 30. Brazil Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Revenue Market Share, 2017-2028
    Figure 33. Turkey Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Peptide Based Metabolic Disorders Therapeutics Revenue, (US$, Mn), 2017-2028
    Figure 37. AstraZeneca Peptide Based Metabolic Disorders Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Eli Lilly Peptide Based Metabolic Disorders Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Ipsen Peptide Based Metabolic Disorders Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Merck Peptide Based Metabolic Disorders Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Medical Care
Frequently Asked Questions
Peptide Based Metabolic Disorders Therapeutics Market In Global report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Peptide Based Metabolic Disorders Therapeutics Market In Global report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Peptide Based Metabolic Disorders Therapeutics Market In Global report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports